Belatacept-based immunosuppression in practice: A single center experience

•Our institutional regimen consisted of tacrolimus, Cellcept and belatacept.•Our unique combination therapy minimized rates of acute rejection and eliminated the need for a belatacept bolus•We report 1 (0.84%) graft failure, 3 (2.52%) acute rejections and 0 cases of post-transplant lymphoproliferative disorder•However, our belatacept regimen predisposed patients to a higher incidence of Cytomegalovirus (CMV) viremia, BK viremia and CMV Disease.•Despite favorable outcomes, belatacept's nuance and intravenous administration posed challenges for patients and providers